Total Marrow Irradiation (TMI) with Helical Tomotherapy and Peripheral Blood Progenitor Cell Rescue (PBPC) Following high-Dose Melphalan (Mel) and PBPC as Part of Tandem Autologous Transplant (TAT) for Patients with Multiple Myeloma

VGPR/CR rate of 61% and MRD negativity of 7.6%. The HR cytogenetics group exhibited an OR, VGPR/CR and MRD negativity rates similar to those shown in the SR group (92.8%, 85% and 21.4%, respectively, p>0.05) In conclusion, CyBorD is an efficacious regimen for patients with MM and overall seemed to be well tolerated. Our data is one of the first to show the impact of this regimen on MRD negativity rates and to highlight its role on HR cytogenetics patients who tended to respond to this therapy. However, sustainability of this response in such aggressive group treated with CyBorD needs further evaluation with longer follow-up. Table 1 Clinical Characteristics of patients with MM undergoing single auto-ASCT treated with CyBorD induction at our Institution